2 years ago

NK:IO Secures £1.2M to Advance Off-the-Shelf Cell Therapies for Solid Tumors

  • NK:IO, a London-based company developing off-the-shelf cell therapies for solid tumors, has raised £1.2 million in funding, bringing its total to $5.1 million

  • The round was led by Cancer Research Horizons with participation from Imperial College Enterprise Fund, Start Codon, UK Innovation & Science Seed Fund and Meltwind

  • NK:IO will use the funds for pre-clinical testing of its cell therapy candidates

  • The company's platform activates blood stem cell progenitors for high-yield NK cell production, enabling efficient engineering for next-generation NK cells.

      • ProblemHealthcare

      "Solid tumours are notoriously difficult to treat with current therapies, leading to poor survival rates for patients."

      Solution

      "NK:IO has developed a platform that activates blood stem cell progenitors to yield NK cells with high tumour-killing potency and very high yield cell production, which it believes will be transformative in cancer cell therapy."

      Covered on